Levels of Ischemia-Modified Albumin in Transient Tachypnea of the Newborn

Basit Öğe Kaydı
dc.contributor.authorOztekin, Osman
dc.contributor.authorKalay, Salih
dc.contributor.authorTayman, Cuneyt
dc.contributor.authorNamuslu, Mehmet
dc.contributor.authorCelik, Huseyin Tugrul
dc.date.accessioned2025-10-24T18:09:12Z
dc.date.available2025-10-24T18:09:12Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractAim The aim of the article is to evaluate ischemia-modified albumin (IMA) levels in infants with transient tachypnea of the newborn (TIN) and to find out its relation to the disease severity. Patients and Methods Infants with > 37 weeks of gestation, without any respiratory and cardiac symptoms and without any maternal health problems, and diagnosed as UN were allocated as the study group. Patients with obvious retractions, grunting, hypercarbia (PCO2 > 60 mm Hg) or hypoxia (oxygen saturation < 88% with FIO2 of 0.60) were managed with nasal continuous positive airway pressure (CPAP). During the postnatal 0 to 24 hours, blood samples were collected in 2 mL for IMA. Results A total of 47 patients were diagnosed TIN, and allocated as the study group. Of the 47 patients, 43 patients without respiratory symptoms were enrolled as the control group. IMA levels in TIN were found to be significantly higher (p < 0.05). In addition, IMA levels were significantly increased in the nasal CPAP group versus supplemental oxygen therapy groups (p < 0.05). IMA levels were determined to be significantly higher in the > 3 days of oxygen therapy group (p < 0.05). IMA levels with a cutoff point of 0.87 ABSU, sensitivity of 81.1% and specificity of 69.8% predicted UN (area under the curve [AUC] = 0.85; p < 0.05). IMA levels with > 0.98 ABSU, 78% sensitivity, and 86% specificity indicated the prediction of CPAP requirement (AUC = 0.86; p < 0.05). Conclusion IMA levels were significantly higher in infants with diagnosed TTN. Therefore, IMA may be used as a new marker for predicting UN and disease severity.
dc.identifier.doi10.1055/s-0034-1381319
dc.identifier.endpage198
dc.identifier.issn0735-1631
dc.identifier.issn1098-8785
dc.identifier.issue2
dc.identifier.pmid24915561
dc.identifier.scopus2-s2.0-84939891245
dc.identifier.scopusqualityQ1
dc.identifier.startpage193
dc.identifier.urihttps://doi.org/10.1055/s-0034-1381319
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3521
dc.identifier.volume32
dc.identifier.wosWOS:000348628800012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherThieme Medical Publ Inc
dc.relation.ispartofAmerican Journal Of Perinatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjecttransient tachypnea of the newborn; ischemia-modified albumin; newborn
dc.titleLevels of Ischemia-Modified Albumin in Transient Tachypnea of the Newborn
dc.title.alternativeLevels of ischemia-modified albumin in transient tachypnea of the newborn
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu